论文部分内容阅读
盐酸氟桂嗪(Flunarizine HCl,Siebelium R14590)系双氟哌嗪衍生物,1970年德国在脑益嗪的基础上首先合成,1977年比利时首先投产,作为治疗脑血管病的新药问世,由于疗效好,副作用小,得到日益广泛的应用。国内1982年由郑州大学化学系药物研究组合成,1988年浙川制药厂经国家批准后正式投入批量生产。药理作用本药系新型钙慢通道阻滞剂,从临床观点出发,Singh 将钙慢通道阻滞剂分为四型。盐酸氟桂嗪属于第3型钙拮抗剂,其主要药理如下:1、为长效及高效钙慢通道阳滞剂,选择性作用于血管平滑肌细胞的钙通道上,阳滞 ca~(++)进入细胞内,而对心肌细胞的钙通道
Flunarizine HCl (Siebelium R14590) is a derivative of bisopiperazine. In 1970, Germany first synthesized on the basis of cerebral yinzine. In 1977, Belgium first put into production as a new drug for the treatment of cerebrovascular disease. Because of its good curative effect , Side effects, get more and more widely used. Domestic in 1982 by the Department of Chemistry, Zhengzhou University, Department of Pharmaceutical Research into the composition, Zhejiang 1988 Zhejiang Pharmaceutical Factory approved by the state formally put into mass production. Pharmacological effects The drug is a new type of calcium channel blockers, from a clinical point of view, Singh calcium slow channel blockers are divided into four types. Flunarizine hydrochloride belongs to type 3 calcium antagonist, and its main pharmacological actions are as follows: 1. As a long-acting and high-efficiency calcium channel blocker, it selectively acts on the calcium channel of vascular smooth muscle cells, ) Into the cell, while on the calcium channels of the cardiomyocytes